Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01870726
Title Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Recruitment Terminated
Gender
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

glioblastoma

Therapies

Buparlisib + Capmatinib

Age Groups: adult
Covered Countries USA | ESP | DEU

Additional content available in CKB BOOST